Blueprint Medicines Corporation
BPMC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $508,824 | $249,380 | $204,036 | $180,080 |
| % Growth | 104% | 22.2% | 13.3% | – |
| Cost of Goods Sold | $20,163 | $12,796 | $17,813 | $17,934 |
| Gross Profit | $488,661 | $236,584 | $186,223 | $162,146 |
| % Margin | 96% | 94.9% | 91.3% | 90% |
| R&D Expenses | $341,433 | $427,720 | $477,419 | $601,033 |
| G&A Expenses | $262,668 | $278,241 | $219,274 | $181,793 |
| SG&A Expenses | $359,272 | $295,141 | $237,374 | $195,293 |
| Sales & Mktg Exp. | $96,604 | $16,900 | $18,100 | $13,500 |
| Other Operating Expenses | $0 | $0 | $8,948 | $7,801 |
| Operating Expenses | $700,705 | $722,861 | $723,741 | $804,127 |
| Operating Income | -$212,044 | -$486,277 | -$549,253 | -$648,460 |
| % Margin | -41.7% | -195% | -269.2% | -360.1% |
| Other Income/Exp. Net | $146,181 | -$19,739 | -$14,763 | $897 |
| Pre-Tax Income | -$65,863 | -$506,016 | -$552,281 | -$641,084 |
| Tax Expense | $1,226 | $968 | $5,236 | $3,001 |
| Net Income | -$67,089 | -$506,984 | -$557,517 | -$644,085 |
| % Margin | -13.2% | -203.3% | -273.2% | -357.7% |
| EPS | -1.07 | -8.37 | -9.35 | -11.01 |
| % Growth | 87.2% | 10.5% | 15.1% | – |
| EPS Diluted | -1.07 | -8.37 | -9.35 | -11.01 |
| Weighted Avg Shares Out | 62,857 | 60,558 | 59,642 | 58,518 |
| Weighted Avg Shares Out Dil | 62,857 | 60,558 | 59,642 | 58,518 |
| Supplemental Information | – | – | – | – |
| Interest Income | $40,655 | $32,812 | $0 | $2,386 |
| Interest Expense | $68,806 | $51,605 | $16,767 | $0 |
| Depreciation & Amortization | $16,291 | $11,665 | $20,099 | $12,785 |
| EBITDA | $19,234 | -$470,356 | -$515,415 | -$628,299 |
| % Margin | 3.8% | -188.6% | -252.6% | -348.9% |